Helper T Cell-17

(STAT3)

(STAT5)

“Regulatory T Cell”

“Autoimmune Disease”

Sakaguchi S et al. Immunologic Self-Tolerance Maintained by Activated T Cells Expressing IL-2 Receptor α-Chains (CD25).J Immunol. 1995.

Langrish CL et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.JEM. 2005.

Figure 1. T cells and inflammatory macrophages enter the CNS of MOG-immunized IL-23p19 mice. (A) Phenotypic analysis of CNS-infiltrating cells in the brains of WT and IL-23p19 mice at day 7 (before EAE onset) after immunization with MOG/CFA. (B) Intracellular cytokine staining of day 7 CNS-infiltrating cells from WT and IL-23p19 mice after 18 h of stimulation with 100 μg/ml MOG peptide, all plots are gated on live CD4 T cells. Data are representative of five separate experiments.

Bettelli E et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Nature. 2006.

Figure 1 | Inhibition of T reg development by different cytokines.

Figure 2 | Cytokines required for the generation of TH 17 cells.

Figure 3 | Reciprocal expression of Foxp3

and IL-17 in T cells during differentiation.

自己免疫疾患

第弐拾九話

多発性硬化症(Multiple Sclerosis, MS)

・空間的多発

・時間的多発

・MBP(Myelin Basic Protein)

・オリゴクローナルバンド

関節リウマチ(Rheumatoid Arthritis, RA)

クローン病(Crohn’s Disease, CD)

潰瘍性大腸炎(Crohn’s Disease, CD)

分子標的療法

・インフリキシマブ　（メミケード ® ）　→　抗 TNF-α 抗体

・リツキシマブ　（リツキサン ® ）　→　抗 CD20 抗体

・トシリズマブ　（アクテムラ ® ）　→　抗 IL-6 抗体

・ゲフェチニブ　（イレッサ ® ）　→　選択的チロシンキナーゼ阻害剤

・？ズマブ　（？ ® ）　→　抗 IL-17 抗体？

人類

補完計画

つづく